Showing results (241-250 of 258) with videos related to
Sort By:
Pageof 26
Anticancer Research|August 27, 2011
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationGeorge Fountzilas, Helen P Kourea, Mattheos Bobos, et al.Plos One|August 8, 2013
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)George Pentheroudakis, Vassiliki Kotoula, Anastasia G Eleftheraki, et al.Plos One|October 10, 2015
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) StudyGeorge Papaxoinis, Vassiliki Kotoula, Zoi Alexopoulou, et al.Clinical Colorectal Cancer|July 8, 2018
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal CancerGeorge Pentheroudakis, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.BMC Cancer|March 30, 2013
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trialsGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.Journal of Translational Medicine|February 15, 2017
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology GroupAmanda Psyrri, Konstantine T Kalogeras, Ralph M Wirtz, et al.Oncology Letters|December 6, 2021
mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumabVassiliki Rapti, Evangelia Moirogiorgou, Georgia-Angeliki Koliou, et al.Journal for Immunotherapy of Cancer|October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K de Klerk, Anuj K Patel, Sarah Derks, et al.Oncotarget|February 1, 2020
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine InitiativeElena Fountzilas, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.Cancers|November 26, 2022
Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational StudyNikolaos Spathas, Anna C Goussia, Georgia-Angeliki Koliou, et al.Pageof 26